NDA 219249 · Genentech INC
Itovebi
Inavolisib · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewCDER novel approval, Oct 10, 2024: To treat locally advanced or metastatic breast cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 10, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
34
5 Phase 3, 17 recruiting
FAERS reports
670
465 serious, 32 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 21, 2026.
ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] . ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. ( 1 , 14.1 )
Mechanism: Inavolisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. In vitro, inavolisib induced the degradation of mutated PI3K catalytic alpha subunit p110α (encoded by the PIK3CA gene), inhibited phosphorylation of the downstream target AKT, reduced cellular proliferation, and induced apoptosis in PIK3CA -mutated breast cancer cell lines. In vivo, inavolisib reduced tumor growth in PIK3CA -mutated, estrogen receptor-positive, breast cancer xenograft models. The combination of inavolisib with palbociclib and fulvestrant increased tumor...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2026 Supplement 4 · Efficacy LetterLabel
- Oct 10, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
2 products under this application
- ITOVEBI · INAVOLISIB 9MG · TABLET, ORAL · Prescription
- ITOVEBI · INAVOLISIB 3MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Inavolisib" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruiting
MedSIRAcademic, hospital or other
NCT05708235 · 976 participants (planned) · Start Apr 1, 2024 · Primary completion Jun 30, 2028
Drug: Giredestrant; Abemaciclib and 2 more · For: Breast Cancer
Sites: A Coruña, Spain; Alicante, Spain; Barcelona, Spain · 41 sites in all
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05768139 · 880 participants (planned) · Start Apr 17, 2023 · Primary completion Jul 2030
Drug: STX-478; Fulvestrant and 9 more · For: Breast Cancer; Solid Tumors, Adult
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 65 sites in all
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04929223 · 542 participants (planned) · Start Oct 22, 2021 · Primary completion Aug 31, 2030
Drug: Inavolisib; Bevacizumab and 7 more · For: Metastatic Colorectal Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 84 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04449874 · 498 participants (planned) · Start Jul 29, 2020 · Primary completion Dec 31, 2027
Drug: GDC-6036; Atezolizumab and 5 more · For: Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors
Sites: Duarte, California; La Jolla, California; Orange, California · 63 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06790693 · 450 participants (planned) · Start Apr 9, 2025 · Primary completion Jan 31, 2032
Drug: Inavolisib; Placebo and 2 more · For: Breast Cancer
Sites: Goodyear, Arizona; Phoenix, Arizona; Burbank, California · 242 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05646862 · 420 participants (planned) · Start Jun 7, 2023 · Primary completion Nov 13, 2026
Drug: Inavolisib; Fulvestrant and 4 more · For: Breast Cancer
Sites: Greenbrae, California; Los Alamitos, California; Los Angeles, California · 210 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyperglycaemia160
- diarrhoea100
- blood glucose increased93
- fatigue67
- nausea65
- neutropenia48
- stomatitis43
- white blood cell count decreased39
- decreased appetite34
- diabetic ketoacidosis34
- asthenia33
- thrombocytopenia31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 10 |
| 2023 | 2 |
| 2024 | 16 |
| 2025 | 297 |
| 2026 | 342 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Itovebi (Inavolisib)
2024 spending
$1.3M
Beneficiaries
39
56 claims
Per beneficiary
$32,837
$658.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,280,636 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
Turner NC, Im SA, Saura C, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Comparative Study
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Jhaveri KL, Im SA, Saura C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Wedam S, Narayan P, Gittleman H, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Jhaveri KL, Accordino MK, Bedard PL, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.
Im SA, Kalinsky K, Jhaveri KL, et al. · ESMO Open 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D, Song K, Johnson RM, et al. · Clin Cancer Res 2026 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.